Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00096
|
|||||
| Drug Name |
Trifluridine
|
|||||
| Synonyms |
1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione; 2'-Deoxy-5-(trifluoromethyl)uridine; 2'-Deoxy-5-trifluoromethyluridine; 5-(Trifluoromethyl)-2'-deoxyuridine; 5-(Trifluoromethyl)deoxyuridine; 5-Trifluoro-2'-deoxythymidine; 5-Trifluoromethyl-2'-deoxyuridine; 5-Trifluoromethyl-2-deoxyuridine; 5-Trifluorothymidine; Alpha,alpha,alpha-Trifluorothymidine; CF3dUrd; F3DThd; F3T; F3TDR; Fluridine; HS-0007; TFDU; TRIFLUOROTHYMIDINE; Trifluoridine; Trifluoromethyldeoxyuridine; Trifluorothymine deoxyriboside; Trifluridina; Trifluridina [INN-Spanish]; Trifluridine (USP/INN);Viroptic, Trifluorothymidine, Trifluridine; Trifluridine [USAN:INN]; Trifluridinum; Trifluridinum [INN-Latin]; Virophta; Viroptic; Viroptic (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Herpes simplex virus infection [ICD11: 1F00] | Approved | [1] | |||
| Therapeutic Class |
Antiviral Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C10H11F3N2O5
|
|||||
| Canonical SMILES |
C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O
|
|||||
| InChI |
InChI=1S/C10H11F3N2O5/c11-10(12,13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2,5-7,16-17H,1,3H2,(H,14,18,19)/t5-,6+,7+/m0/s1
|
|||||
| InChIKey |
VSQQQLOSPVPRAZ-RRKCRQDMSA-N
|
|||||
| CAS Number |
CAS 70-00-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 296.2 | Topological Polar Surface Area | 99.1 | ||
| Heavy Atom Count | 20 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
-0.5
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103321204
, 104023317
, 104253375
, 104311541
, 118048237
, 12014784
, 12149237
, 124757493
, 124800643
, 125164297
, 126667216
, 129521334
, 131404691
, 134223275
, 134338045
, 134971818
, 135681084
, 135692274
, 136369804
, 137000771
, 137005241
, 137213977
, 144205964
, 14751529
, 14849367
, 152058901
, 160963778
, 163835390
, 170464911
, 172092201
, 172919625
, 174483143
, 175266936
, 175612130
, 176484794
, 179116934
, 24900027
, 29225252
, 46506192
, 50054714
, 56422883
, 57323294
, 626314
, 77174799
, 7847457
, 7980831
, 8139891
, 8153936
, 87560183
, 93815015
|
|||||
| ChEBI ID |
CHEBI:75179
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | CNT1 | Transporter Info | Concentrative nucleoside transporter 1 | Substrate | [2] | |
| ENT1 | Transporter Info | Equilibrative nucleoside transporter 1 | Substrate | [2] | ||
| ENT2 | Transporter Info | Equilibrative nucleoside transporter 2 | Substrate | [2] | ||
| OAT1 | Transporter Info | Organic anion transporter 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Trifluridine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Lonsurf, INN-trifluridine/tipiracil. | |||||
| 3 | Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs. J Pharmacol Exp Ther. 2000 Sep;294(3):844-9. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.